Fujifilm Irvine Technologies, a leader in the innovation and manufacturing of cell culture solutions for the global life sciences and medical markets, has announced its assisted reproductive technology in China ( ART) product portfolio has been expanded.
Amid a recent surge of layoffs in the biopharma industry, two contract manufacturers have each cut more than 50 jobs, filings show.
SANTA ANA, Calif.--(BUSINESS WIRE)--FUJIFILM Irvine Scientific, Inc., a global leader in the innovation and manufacture of cell culture solutions for the Life Science and Medical markets, today announced the addition of the Life Whisperer Genetics module to its Life Whisperer software package (launched in 2021)1, enabling non-invasive evaluation of embryo genetic integrity during in vitro fertilization (IVF). Life Whisperer Genetics used in conjunction with Life Whisperer Viability uniquely aids in the clinical selection of blastocysts that may have a greater likelihood of being euploid and resulting in pregnancy using a single platform.
FUJIFILM Irvine Scientific Expands BalanCD CHO Media Platform Portfolio for Bioprocessing
FUJIFILM Irvine Scientific Launches HEK293 Feed, Specifically Designed for Viral Vector Production
Fujifilm Irvine Scientific Inc., a leader in the development and manufacture of serum-free and chemically defined cell culture media for bioproduction and cell therapy manufacturing, has launched its BalanCD HEK293 Viral Feed. The chemically defined, nutrient-based HEK293-specific feed medium is designed to boost adeno-associated viral vector (AAV) production for gene therapy applications and viral vector-based vaccines.
Fujifilm Corporation announced a $188 million investment to establish a cell culture media manufacturing facility in Research Triangle Park (RTP), NC. The new site will be operated by Fujifilm Irvine Scientific, Inc., a subsidiary of Fujifilm Corporation, and a leader in the development and manufacture of advanced cell culture solutions for life science research, bioproduction, cell therapy manufacturing, and medical applications. The new facility is planned to ensure that Fujifilm Irvine Scientific can meet increasing market demands for high quality cell culture media solutions.
Fujifilm, which has been on a $1.6 billion expansion tear, will drop $188 million to build a cell culture media manufacturing facility in North Carolina’s Research Triangle Park.
SANTA ANA, Calif.--(BUSINESS WIRE)--FUJIFILM Irvine Scientific, Inc., a world leader in the development and manufacture of serum-free and chemically defined cell culture media for bioproduction and cell therapy manufacturing, today announced that its PRIME-XV Stem FreezIS DMSO-Free* cryopreservation medium is to be used as an excipient in a FDA-authorized clinical trial conducted by Vitro Biopharma.
Fujifilm Irvine Scientific, a provider of the development and manufacture of serum-free and chemically defined cell culture media for bioproduction and cell therapy manufacturing, has completed its Armstrong Cell Culture Center of Excellence. More than doubling the R&D facility’s footprint, the new state-of-the-art center enables the company to expand its capabilities in cutting-edge discovery research, bioproduction, cell and gene therapy, Assisted Reproductive Technologies (ART) and cytogenetics.